Following the annual J.P.
In a research report issued today, Brean Capital analyst Jonathan Aschoff maintained a Hold rating on Biomarin Pharmaceutical (NASDAQ:BMRN), as the company reported total revenue of …
In a research note released today, Janney Capital analyst Kimberly Lee maintained a Buy rating on BioMarin Pharmaceutical (BMRN) and a $65 price target, which represents …
